Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Filing Details

Accession Number:
0001209191-12-024645
Form Type:
4
Zero Holdings:
No
Publication Time:
2012-04-27 15:30:29
Reporting Period:
2012-04-26
Filing Date:
2012-04-27
Filing Date Changed:
2012-04-27
Accepted Time:
2012-04-27 16:30:29
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1131324 Genomic Health Inc GHDX Services-Medical Laboratories (8071) 770552594
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1235118 S Randall Livingston Stanford University
Bldg 60, Main Quadrangle
Stanford CA 94305
Yes No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2012-04-26 2,000 $1.33 8,149 No 4 M Direct
Common Stock Disposition 2012-04-26 2,000 $28.21 6,149 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Stock Option (right to buy) Disposition 2012-04-26 2,000 $0.00 2,000 $1.33
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
7,346 2014-10-06 No 4 M Direct
Footnotes
  1. This sale of common stock was effected persuant to a Rule 10b5-1 sales plan adopted by the reporting person on February 18, 2011.
  2. Reporting person undertakes to provide upon request by the Securities and Exchange Commission, the issuer or a securityholder of the issuer detailed information regarding the price and number of shares sold within the range indicated.
  3. Represents weighted average sale price. Actual sale prices ranged from $28.05 to $28.42.
  4. The option became exercisable as to 25% of the shares on October 6, 2005,and became exercisable as to 1/48th of the shares each full month thereafter.